Skip to main content
Top

30-04-2024 | Colorectal Cancer | Original Article

A comprehensive characterization of the spectrum of MUTYH germline pathogenic variants in Latin America

Authors: Patricia Esperon, Florencia Neffa, Walter Pavicic, Florencia Spirandelli, Karin Alvarez, María José Mullins, Benedito Mauro Rossi, Rodrigo Felipe Góngora e Silva, Carlos Vaccaro, Francisco Lopéz-Köstner, Jorge Rugeles, Adriana Della Valle, Mev Dominguez-Valentin

Published in: Familial Cancer

Login to get access

Abstract

MUTYH-Associated Polyposis (MAP) is caused by biallelic pathogenic germline variants in the MUTYH gene. However, individuals harboring monoallelic MUTYH pathogenic variants in the presence of a positive family history have been reported to have a twofold increased risk of colorectal cancer (CRC) and extra colonic cancers. Our aim was to characterize the spectrum of monoallelic and biallelic germline MUTYH pathogenic variants in Latin American patients and to describe their clinical and genetic characteristics. Patients were identified from eight high-risk genetic cancer centers of five Latin American countries. Statistical analysis was performed using the two-sided P test using the Vassarstats statistical tools. Statistical significance was set at a p value ≤ 0.05. Of the 105 unrelated patients with cancer or colorectal polyposis, 84.8% and 15.2% carried pathogenic monoallelic and biallelic MUTYH variants, respectively. The most common pathogenic variants were p.Gly396Asp and p.Tyr179Cys (55% and 23%, respectively). The mean age at first diagnosis was 48.29 years (range 31–71) and 49.90 years (range 27–87) in biallelic and monoallelic MUTYH patients, respectively. CRC was the only cancer diagnosed in patients with biallelic MUTYH pathogenic variants (75%), while breast cancer (46.1%) was more common than CRC (24.7%) in individuals with monoallelic MUTYH pathogenic variants. We reported a high frequency of European founder variants in our diverse population. Some phenotypic differences from current studies were identified, such as a higher breast cancer burden in monoallelic carriers and a complete absence of extra-colon tumors in biallelic patients.
Literature
1.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149(4):778–789CrossRef Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149(4):778–789CrossRef
2.
go back to reference Medina Pabón MA, Babiker HM (2022) A review of hereditary colorectal cancers. StatPearls Publishing, StatPearls Medina Pabón MA, Babiker HM (2022) A review of hereditary colorectal cancers. StatPearls Publishing, StatPearls
3.
go back to reference Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K et al (2017) Clinical Cancer Genetics Consortia. Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines. Hered Cancer Clin Pract 15:3CrossRefPubMedPubMedCentral Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K et al (2017) Clinical Cancer Genetics Consortia. Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines. Hered Cancer Clin Pract 15:3CrossRefPubMedPubMedCentral
4.
go back to reference Hampel H (2018) Population screening for hereditary colorectal cancer. Surg Oncol Clin N Am 2:319–325CrossRef Hampel H (2018) Population screening for hereditary colorectal cancer. Surg Oncol Clin N Am 2:319–325CrossRef
5.
go back to reference Sutcliffe EG, Bartenbaker Thompson A, Stettner AR, Marshall ML, Roberts ME et al (2019) Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis. Fam Cancer 18(2):203–209CrossRefPubMed Sutcliffe EG, Bartenbaker Thompson A, Stettner AR, Marshall ML, Roberts ME et al (2019) Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis. Fam Cancer 18(2):203–209CrossRefPubMed
6.
go back to reference Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM et al (2008) Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 135(6):2014–2018CrossRefPubMed Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM et al (2008) Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 135(6):2014–2018CrossRefPubMed
7.
go back to reference Pitroski C, Cossio S, Koehler-Santos P, Graudenz M, Prolla J, Ashton-Prolla P (2011) Frequency of the common germline MUTYH mutations p. G396D and p.Y179C in patients diagnosed with colorectal cancer in Southern Brazil. Int J Colorectal Dis 26:841–846CrossRefPubMed Pitroski C, Cossio S, Koehler-Santos P, Graudenz M, Prolla J, Ashton-Prolla P (2011) Frequency of the common germline MUTYH mutations p. G396D and p.Y179C in patients diagnosed with colorectal cancer in Southern Brazil. Int J Colorectal Dis 26:841–846CrossRefPubMed
8.
go back to reference Nielsen M, de Joerink-van Beld MC, Jones N, Vogt S, Tops CM, Vasen HFA et al (2009) Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 136:471–476CrossRefPubMed Nielsen M, de Joerink-van Beld MC, Jones N, Vogt S, Tops CM, Vasen HFA et al (2009) Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 136:471–476CrossRefPubMed
9.
go back to reference Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, Haile R et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136(4):1251–1260CrossRefPubMed Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, Haile R et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136(4):1251–1260CrossRefPubMed
10.
go back to reference Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10(1):1–9CrossRefPubMedPubMedCentral Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10(1):1–9CrossRefPubMedPubMedCentral
11.
go back to reference Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, Wijnen JT, Vasen HF, Weiss MM, Klijn JG, Devilee P, Hes FJ, Schutte M (2010) Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. Breast Cancer Res Treat 124(3):635–641CrossRefPubMed Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, Wijnen JT, Vasen HF, Weiss MM, Klijn JG, Devilee P, Hes FJ, Schutte M (2010) Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. Breast Cancer Res Treat 124(3):635–641CrossRefPubMed
12.
go back to reference Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, Edwards E, Evans DG, Maher ER, Vasen HF, Hes FJ, Aretz S et al (2009) Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137:489–494CrossRefPubMed Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, Edwards E, Evans DG, Maher ER, Vasen HF, Hes FJ, Aretz S et al (2009) Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137:489–494CrossRefPubMed
14.
go back to reference Rodriguez-Rojas LX, Candelo E, Pachajoa H, Garcia-Robledo JE, Nastasi-Catanese JA, Olave-Rodriguez JA, Zambrano AR (2023) The unique spectrum of MUTYH germline mutations in colombian patients with extracolonic carcinomas. Appl Clin Genet 16:53–62CrossRefPubMedPubMedCentral Rodriguez-Rojas LX, Candelo E, Pachajoa H, Garcia-Robledo JE, Nastasi-Catanese JA, Olave-Rodriguez JA, Zambrano AR (2023) The unique spectrum of MUTYH germline mutations in colombian patients with extracolonic carcinomas. Appl Clin Genet 16:53–62CrossRefPubMedPubMedCentral
15.
go back to reference Vaccaro CA, López-Kostner F, Adriana DV, Palmero EI, Rossi BM, Antelo M et al (2019) From colorectal cancer pattern to the characterization of individuals at risk: picture for genetic research in Latin America. Int J Cancer 145(2):318–326CrossRefPubMed Vaccaro CA, López-Kostner F, Adriana DV, Palmero EI, Rossi BM, Antelo M et al (2019) From colorectal cancer pattern to the characterization of individuals at risk: picture for genetic research in Latin America. Int J Cancer 145(2):318–326CrossRefPubMed
17.
go back to reference Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I et al (2009) C. APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet 76:242–255CrossRefPubMed Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I et al (2009) C. APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet 76:242–255CrossRefPubMed
18.
go back to reference Cheadle JP, Sampson JR (2007) MUTYH-associated polyposis–from defect in base excision repair to clinical genetic testing. DNA Repair 6:274–279CrossRefPubMed Cheadle JP, Sampson JR (2007) MUTYH-associated polyposis–from defect in base excision repair to clinical genetic testing. DNA Repair 6:274–279CrossRefPubMed
19.
go back to reference Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27:3975–3980CrossRefPubMed Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27:3975–3980CrossRefPubMed
20.
go back to reference Lipton L, Halford SE, Johnson V, Novelli MR, Jones A, Cummings C et al (2003) Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63:7595–7599PubMed Lipton L, Halford SE, Johnson V, Novelli MR, Jones A, Cummings C et al (2003) Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63:7595–7599PubMed
22.
go back to reference Nielsen M, Infante E, Brand R (1993-2024) MUTYH Polyposis. 2012 Oct 4 [Updated 2021 May 27]. In: Adam MP, Feldman J, Mirzaa GM et al (eds). GeneReviews®. University of Washington, Seattle Nielsen M, Infante E, Brand R (1993-2024) MUTYH Polyposis. 2012 Oct 4 [Updated 2021 May 27]. In: Adam MP, Feldman J, Mirzaa GM et al (eds). GeneReviews®. University of Washington, Seattle
23.
go back to reference Gupta S, Weiss JM, Axell L, Burke CA, Chen LM, Chung DC, Clayback KM, Dallas S, Felder S, Giardiello FM et al (2024) NCCN genetic/familial high-risk assessment: colorectal version 2.2023. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Accessed 12 Mar 2024. https://www.nccn.org/home/ Gupta S, Weiss JM, Axell L, Burke CA, Chen LM, Chung DC, Clayback KM, Dallas S, Felder S, Giardiello FM et al (2024) NCCN genetic/familial high-risk assessment: colorectal version 2.2023. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Accessed 12 Mar 2024. https://​www.​nccn.​org/​home/​
24.
go back to reference Magrin L, Fanale D, Brando C et al (2022) MUTYH-associated tumor syndrome: the other face of MAP. Oncogene 41:2531–2539CrossRefPubMed Magrin L, Fanale D, Brando C et al (2022) MUTYH-associated tumor syndrome: the other face of MAP. Oncogene 41:2531–2539CrossRefPubMed
25.
go back to reference Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146(5):1208–1211CrossRefPubMed Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146(5):1208–1211CrossRefPubMed
26.
go back to reference Thompson AB, Sutcliffe EG, Arvai K, Roberts ME, Susswein LR et al (2022) Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer. Fam Cancer 21:415–422CrossRefPubMed Thompson AB, Sutcliffe EG, Arvai K, Roberts ME, Susswein LR et al (2022) Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer. Fam Cancer 21:415–422CrossRefPubMed
27.
go back to reference Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440–451CrossRefPubMedPubMedCentral Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440–451CrossRefPubMedPubMedCentral
Metadata
Title
A comprehensive characterization of the spectrum of MUTYH germline pathogenic variants in Latin America
Authors
Patricia Esperon
Florencia Neffa
Walter Pavicic
Florencia Spirandelli
Karin Alvarez
María José Mullins
Benedito Mauro Rossi
Rodrigo Felipe Góngora e Silva
Carlos Vaccaro
Francisco Lopéz-Köstner
Jorge Rugeles
Adriana Della Valle
Mev Dominguez-Valentin
Publication date
30-04-2024
Publisher
Springer Netherlands
Published in
Familial Cancer
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-024-00382-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine